Haichuang Biotech secures tens of millions in Series A funding led by Sunz Fund

On October 17, Shenzhen Haichuang Biotechnology Co., Ltd. ("Haichuang Biotech"), a Chinese high-tech enterprise dedicated to immunology, officially announced the completion of a Series A financing round totaling tens of millions of RMB. This round was exclusively invested by Sunz Fund, with Lighthouse Capital serving as the exclusive financial advisor. The raised funds will be allocated towards the company's new product development and iteration, brand building, and team expansion.

Founded in 2020, Haichuang Biotech leverages over three decades of immunology research achievements from Shenzhen University's Institute of Allergy & Immunology. With a strategic focus on skin and gut immunology, the company specializes in developing and industrializing anti-aging functional skincare products, functional probiotics, and related bioactive ingredients. It is committed to building a comprehensive portfolio spanning cosmetics, functional foods, pharmaceuticals, and medical devices.

Based on its self-developed Bio-Tracking and Isolation Method (BTIM), Haichuang Biotech has developed the proprietary patented ingredient HEPRO-6A®. This compound demonstrates six key anti-aging activities: anti-photoaging, anti-glycation, antioxidant, anti-inflammatory, antimicrobial, and damage repair. Its synergistic efficacy earned it the "Innovative Ingredient Award" and the "InnoCosme Awards" at CIC 2022. The HEPROA skincare series, featuring HEPRO-6A® as its core component, is now available through e-commerce channels including Tmall, Douyin, and its official WeChat Mini-Program. Despite its premium pricing strategy, the product line maintains a remarkable repurchase rate exceeding 60%, strongly validating its exceptional product efficacy and market acceptance.

China's skincare industry is undergoing a profound transformation, with consumers increasingly moving beyond basic efficacy to seek scientifically-validated precision skincare solutions. According to the latest CBNData survey, over 70% of consumers prefer skin-type-specific regimens, while half actively research product ingredient mechanisms. This trend highlights a clear shift toward precision and science-driven skincare consumption.

This evolving landscape aligns perfectly with Haichuang Biotech's core strength: its deep scientific foundation. The company was co-founded by two esteemed scientists: Professor Liu Zhigang, former Vice Dean of Shenzhen University School of Medicine, and Professor Wang Zhiyao, who holds a PhD in Immunology from the University of Oxford. The core team possesses over 30 years of collective research experience in cutting-edge fields including human microecology, allergy mechanisms, and immunology, having published more than 300 immunology-related academic papers. With doctoral degree holders comprising over 60% of the R&D team, members have previously provided formulation development services for several established skincare manufacturers and established a comprehensive product efficacy evaluation system. The team has also delivered scientific and technical support to listed pharmaceutical companies such as Kexing Biotech and Guangwei Group. This solid scientific foundation and practical experience provide robust technological support for the successful launch of Haichuang Biotech's proprietary brand "HEPROA."